Skip to main content
BMC Infectious Diseases logoLink to BMC Infectious Diseases
. 2021 May 11;21:436. doi: 10.1186/s12879-021-06130-7

Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

Keivan Ranjbar 1,2, Mohsen Moghadami 3,, Alireza Mirahmadizadeh 3,4, Mohammad Javad Fallahi 1,5, Vahid Khaloo 6, Reza Shahriarirad 1,2, Amirhossein Erfani 1,2, Zohre Khodamoradi 5,7, Mohammad Hasan Gholampoor Saadi 2
PMCID: PMC8111051  PMID: 33975548

Correction to: BMC Infect Dis 21, 337 (2021)

https://doi.org/10.1186/s12879-021-06045-3

Following publication of the original article [1], an error was identified in the Abstract section.

The incorrect sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group).

The correct sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group).

The original article has been corrected.

Reference

  • 1.Ranjbar K, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21:337. doi: 10.1186/s12879-021-06045-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from BMC Infectious Diseases are provided here courtesy of BMC

RESOURCES